Results 251 to 260 of about 2,461,363 (302)
Some of the next articles are maybe not open access.
Antiplatelet therapy and exodontia
The Journal of the American Dental Association, 2015This is a review of the management considerations regarding exodontia for patients taking antithrombotic medications that affect platelet function or aggregation.The authors reviewed the literature, focusing on the indications and mechanisms of antiplatelet therapy and the perioperative management of patients taking these agents who require exodontia ...
Willem H, Schreuder, Zachary S, Peacock
openaire +2 more sources
Antiplatelet Therapy in Diabetes
Endocrinology and Metabolism Clinics of North America, 2018Cardiovascular disease (CVD) is a significant cause of morbidity and mortality among patients with diabetes mellitus (DM). Increased platelet reactivity among patients with DM contributes to disproportionately high levels of atherothrombotic CVD. Consequently, there has been tremendous interest in exploring the role of antiplatelet therapies in DM to ...
Arjun, Majithia, Deepak L, Bhatt
openaire +2 more sources
Exodontia and Antiplatelet Therapy
Journal of Oral and Maxillofacial Surgery, 2008The fear of excessive bleeding often prompts the physician to stop long-term, low-dose antiplatelet therapy before any surgical procedure. This may put the patient at risk of an adverse thromboembolic event. We undertook an assessment of the incidence of prolonged postoperative bleeding after dental extractions among patients on uninterrupted ...
Balasubramanian, Krishnan +2 more
openaire +2 more sources
Pharmacogenetics of Antiplatelet Therapy
Current Atherosclerosis Reports, 2014There has been substantial progress toward understanding and investigating the specific genetic factors that influence interindividual variations in platelet-directed therapy. There has also been substantial progress toward better understanding of the pharmacogenetics of drug metabolism and phamacodynamic response to platelet antagonists.
Patrick L, Daly, Richard C, Becker
openaire +2 more sources
The American Journal of Medicine, 1996
The major clinical indication for antiplatelet therapy has been the prevention of arterial thrombosis. Arterial thrombi are composed of predominantly platelets formed under conditions of elevated shear stress at sites of atherosclerotic vascular injury and disturbed blood flow.
openaire +2 more sources
The major clinical indication for antiplatelet therapy has been the prevention of arterial thrombosis. Arterial thrombi are composed of predominantly platelets formed under conditions of elevated shear stress at sites of atherosclerotic vascular injury and disturbed blood flow.
openaire +2 more sources
Hospital Medicine, 2000
Within the last few years antiplatelet therapy has developed exponentially, with new agents being tested in an increasing number of clinical scenarios. The mechanism of action of these newer agents and evidence of benefit is prevented in this review.
openaire +2 more sources
Within the last few years antiplatelet therapy has developed exponentially, with new agents being tested in an increasing number of clinical scenarios. The mechanism of action of these newer agents and evidence of benefit is prevented in this review.
openaire +2 more sources
Antiplatelet and antithrombin therapy
Coronary Artery Disease, 1994The contemporary pharmacologic treatment of acute myocardial infarction (AMI) includes reperfusion via a thrombolytic agent as well as adjunctive therapy with aspirin and heparin (1). Despite the advances made, current management is limited by the fact that infarct-related artery patency is achieved in only 60–80% of patients at 90 min and Thrombolysis
A, Fernández-Ortiz +2 more
openaire +2 more sources
Monitoring of Antiplatelet Therapy
2023In the late 1990s, the antithrombotic antiplatelet agent, clopidogrel, a P2Y12 inhibitor, was introduced. Around the same time, there was an increase in a number of new methods to measure platelet function (e.g., PFA-100 in 1995), and this has continued.
openaire +2 more sources
Antiplatelet therapy – ticagrelor
Hämostaseologie, 2012SummaryTicagrelor, a cyclopentyltriazolopyrimidine (CPTP), is the representative of a new chemical class of P2Y12 receptor inhibitors that differ from thienopyridines (ticlopidin, clopidogrel, prasugrel) as ticagrelor is not a prodrug requiring active biotransformation by cytochromes in the liver and thus is characterized by a more rapid, more ...
E, Giannitsis, H A, Katus
openaire +2 more sources
Current Atherosclerosis Reports, 2011
Advances in antiplatelet therapy have significantly improved outcomes in patients with ischemic heart disease. Thienopyridines remain a cornerstone of therapy along with aspirin. Recently, concerns have been raised about the use of clopidogrel due to its pharmacokinetic and pharmacogenetic interpatient variability.
Luke, Kim +3 more
openaire +2 more sources
Advances in antiplatelet therapy have significantly improved outcomes in patients with ischemic heart disease. Thienopyridines remain a cornerstone of therapy along with aspirin. Recently, concerns have been raised about the use of clopidogrel due to its pharmacokinetic and pharmacogenetic interpatient variability.
Luke, Kim +3 more
openaire +2 more sources